Article Figures & Data
Figures
- FIGURE 1.
Coregistered whole-body SPECT/CT scans of a single female nude mouse grafted with HT29 tumor cells acquired 3 (A), 20 (B), 45 (C), 69 (D), and 93 (E) h after injection of 130.7 MBq of 177Lu-3BP-227. Arrows show HT29 tumors. SPECT data were scaled to 0%–75% of maximum count value in the tumor of the respective dataset. B = Urinary bladder; K = Kidney.
- FIGURE 2.
Uptake of 177Lu-3BP-227 in selected tissues 3, 20, and 69 h after injection (mean %ID/g ± SD). n = 5 mice per time point. p.i. = after injection.
- FIGURE 3.
(A) Therapeutic effect of 177Lu-3BP-227 in female nude mice grafted with HT29 cells. Tumor volume data are normalized to measurement at day of 177Lu-3BP-227 injection and represented as median and interquartile range. (B) Kaplan–Meier plot showing tumor progression of HT29 in same study. Endpoint was set at reaching relative tumor volume of ≥ 2. Control: n = 10; 165-MBq group: n = 9; 110-MBq group: n = 10.
- FIGURE 4.
Serum concentrations of functional kidney biomarkers—creatinine (A), urea (B), cystatin C (C), and neutrophil gelatinase–associated lipocalin (NGAL) (D)—of female nude mice grafted with HT29 cells obtained after injection of median dose of 165 or 110 MBq of 177Lu-3BP-227 or 0.9% NaCl as control. Sample sizes (165-MBq group/110-MBq group/control)—2/5/6 (A), 2/5/6 (B), 3/5/6 (C), and 3/5/2 (D). Statistical analysis comparing biomarker concentrations was performed by Kruskal–Wallis test, with no significant differences detected.
Additional Files
Supplemental Data
Files in this Data Supplement:
Jump to section
Related Articles
Cited By...
- Synthesis of 64Cu-, 55Co-, and 68Ga-Labeled Radiopharmaceuticals Targeting Neurotensin Receptor-1 for Theranostics: Adjusting In Vivo Distribution Using Multiamine Macrocycles
- Complexes of the neurotensin receptor 1 with small-molecule ligands reveal structural determinants of full, partial, and inverse agonism
- Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted {alpha}-particle therapy
- Mechanistic Biomarkers Informative of Both Cancer and Cardiovascular Disease: JACC State-of-the-Art Review
- Genetic signature of prostate cancer resistant to optimized hK2 targeted alpha-particle therapy
- Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine
- 177Lu-3BP-227 for Neurotensin Receptor 1-Targeted Therapy of Metastatic Pancreatic Adenocarcinoma: First Clinical Results
- NTR Is the New SSTR? Perspective for Neurotensin Receptor 1 (NTR)-Directed Theranostics